Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

NXL - Nexalin Technology Inc Stock Price, Fair Value and News

$1.48-0.02 (-1.33%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

NXL Price Action

Last 7 days

6.3%

Last 30 days

73.9%

Last 90 days

54.6%

Trailing 12 Months

-38.6%

NXL RSI Chart

FebMarAprMayJunJulAugSepOct0102030405060708090

NXL Valuation

Market Cap

27.0M

Price/Earnings (Trailing)

-3.05

Price/Sales (Trailing)

16.93

EV/EBITDA

-2.09

Price/Free Cashflow

-6.31

NXL Price/Sales (Trailing)

2023202420250102030405060

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NXL Fundamentals

NXL Revenue

Revenue (TTM)

966.8K

Rev. Growth (Yr)

-25.88%

Rev. Growth (Qtr)

335.44%

2022202320242025200K400K600K800K1M1.2M1.4M

NXL Earnings

Earnings (TTM)

-8.9M

Earnings Growth (Yr)

-23.08%

Earnings Growth (Qtr)

20.49%

2022202320242025-8M-6M-4M-2M

NXL Profitability

Operating Margin

94.15%

EBT Margin

-787.33%

Return on Equity

-148.42%

Return on Assets

-134.84%

Free Cashflow Yield

-15.84%

NXL Investor Care

Shares Dilution (1Y)

37.21%

Diluted EPS (TTM)

-0.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2022AprJulOct2023AprJulOct2024AprJulOct200K400K600K800K1M1.2M1.4M
Net sales
YearQ1Q2Q3Q4
20250000
2024591.2K796.6K881.7K966.8K
20231.1M948.0K761.3K574.6K
2022438.4K732.7K1.0M1.3M
2021000144.1K
Get all data in R, Python etc through our Historical Stock Data APIs

About Nexalin Technology Inc

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.
 CEO
 WEBSITEnexalin.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES6

Nexalin Technology Inc Frequently Asked Questions

What is the ticker symbol for Nexalin Technology Inc? What does NXL stand for in stocks?

NXL is the stock ticker symbol of Nexalin Technology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nexalin Technology Inc (NXL)?

As of Fri Oct 31 2025, market cap of Nexalin Technology Inc is 27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NXL stock?

You can check NXL's fair value in chart for subscribers.

Is Nexalin Technology Inc a good stock to buy?

The fair value guage provides a quick view whether NXL is over valued or under valued. Whether Nexalin Technology Inc is cheap or expensive depends on the assumptions which impact Nexalin Technology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NXL.

What is Nexalin Technology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Oct 31 2025, NXL's PE ratio (Price to Earnings) is -3.05 and Price to Sales (PS) ratio is 16.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NXL PE ratio will change depending on the future growth rate expectations of investors.